We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.90
Bid: 40.66
Ask: 40.72
Change: -0.90 (-2.15%)
Spread: 0.06 (0.148%)
Open: 42.10
High: 42.10
Low: 40.60
Prev. Close: 41.80
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

9 Feb 2016 07:05

RNS Number : 4402O
Assura PLC
09 February 2016
 

9 February 2016

 

Assura plc

 

Trading Update

 

For the period to 8 February 2016

 

Period of significant growth

 

Assura plc ("Assura"), the UK's leading healthcare REIT, today publishes a trading update for the period from 1 October to 8 February 2016.

 

Step change following successful equity raise

 

On 11 October 2015 Assura completed an equity raise of £300 million, net of expenses, to fund further acquisitions and developments and significantly strengthens the balance sheet. This strengthened financial position improves Assura's standing with its primary customers in the NHS and GPs, greatly increases its ability to take advantage of the considerable ongoing opportunities in the sector and provides scope for negotiating better terms and pricing on future debt facilities.

 

Since the equity raise, the proceeds have been applied in a reduction of long-term debt by £181 million (with additional early prepayment costs as set out below), the temporary repayment of the revolving credit facility of £35 million and 12 property additions with a gross value on completion of £39 million. The property additions consist of ten property acquisitions, one completed development and one completed forward funding agreement and increases the rent roll by £2.3 million with a weighted average unexpired lease term of 21.9 years.

 

New acquisition and development opportunities continue to be identified at a faster pace than the conversion of heads of terms into contractual completion. As a result the immediate pipeline of such opportunities has risen to £135 million from the £125 million announced in October.

 

Further rental growth achieved

 

The annualised rent roll is now £61.8 million (September 2015: £59.6 million) with growth driven primarily from acquisitions.

 

The weighted average annual rent increase was 1.40% on the basis of 111 reviews settled in the financial year to date, which includes an average annual rental growth of 0.89% arising from settled open market rent reviews. 85 of the reviews settled in the period related to 2015 review dates with an annualised increase of 1.51%, mostly driven by stepped uplifts in a small number of rent review clauses and RPI based reviews.

 

Strong financial position

 

As outlined to investors at the time of the recent fundraise a key objective was to strengthen the financial position of Assura and a new medium term target loan to value range of 40% to 50% was announced. Currently the loan to value ratio is below 30%, allowing for significant further investment.

 

In the period Assura successfully negotiated the redemption of £181 million of long term debt held by Aviva Commercial Finance, which had associated early repayment costs of £34 million.

 

Assura currently has £120 million of undrawn facilities and is well placed to take advantage of the opportunities for further consolidation in our sector.

 

Secure and growing dividend

 

A key part of Assura's strategy is providing a secure and growing dividend stream for investors. The quarterly dividend was increased by 10% for the January 2016 payment to 0.55 pence per share or 2.2 pence per share on an annualised basis. At this time Assura also introduced a scrip alternative for shareholders to provide greater flexibility on how dividends are received.

 

Graham Roberts, Chief Executive, commented:

 

"There has been a renewed emphasis from the NHS and politicians recently on addressing the chronic shortage of primary care space in the UK. Assura is ideally placed with the expertise, scale and financial flexibility to support this essential investment in our nation's primary care infrastructure."

 

-ENDS-

For more information, please contact:

 

Assura plc

 

Tel: 01925 420660

Jonathan Murphy

Orla Ball

Carolyn Jones

 

Finsbury

 

Tel: 0207 251 3801

Gordon Simpson

 

Notes to Editors

Assura plc, a constituent of the FTSE 250, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. It owns 305 medical centres nationwide, serving over 3 million patients. At 30 September 2015, Assura's property portfolio was valued at £1,030 million.

 

Further information is available at www.assuraplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFITFIITIIR
Date   Source Headline
16th Apr 20247:40 amRNSDirector/PDMR Shareholding
8th Apr 20244:34 pmRNSDirector/PDMR Shareholding
8th Apr 20247:00 amRNSScrip Dividend Declaration
22nd Mar 20242:18 pmRNSHolding(s) in Company
14th Mar 20248:30 amRNSScrip Calculation Price
6th Mar 20241:26 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSNotice of Dividend
8th Feb 20242:00 pmRNSCapital Markets Event
7th Feb 20242:33 pmRNSDirector/PDMR Shareholding
1st Feb 20249:32 amRNSTotal Voting Rights
16th Jan 20248:26 amRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSTrading Update
9th Jan 20248:59 amRNSDirector/PDMR Shareholding
8th Jan 20247:00 amRNSScrip Dividend Declaration
21st Dec 20234:20 pmRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSScrip Calculation Price
6th Dec 20232:57 pmRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSNotice of Dividend
16th Nov 20237:00 amRNSAssura Plc Interim Results
8th Nov 20232:32 pmRNSDirector/PDMR Shareholding
1st Nov 20237:00 amRNSAppointment of Board Fellow
31st Oct 20237:00 amRNSNotice of Interim Results
31st Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20232:04 pmRNSDirector/PDMR Shareholding
9th Oct 202311:13 amRNSDirector/PDMR Shareholding
9th Oct 20238:11 amRNSScrip Dividend Declaration
9th Oct 20237:00 amRNSRefinancing of RCF & new sustainability linkage
9th Oct 20237:00 amRNSTrading Update
18th Sep 20239:51 amRNSVesting and sale of restricted shares
14th Sep 20239:20 amRNSScrip Calculation Price
31st Aug 20237:00 amRNSNotice of Dividend
24th Aug 20238:36 amRNSHolding(s) in Company
8th Aug 20235:05 pmRNSDirector/PDMR Shareholding
31st Jul 20239:57 amRNSTotal Voting Rights
24th Jul 20237:00 amRNSDevelopment update
14th Jul 20231:47 pmRNSDirector/PDMR Shareholding
13th Jul 20234:47 pmRNSExercise of Nil Cost Options under PSP
12th Jul 20234:36 pmRNSDirector/PDMR Shareholding
10th Jul 202312:38 pmRNSHolding(s) in Company
10th Jul 20239:20 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSScrip Dividend Declaration & Additional Listing
6th Jul 20232:47 pmRNSResult of AGM
6th Jul 202312:28 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSTrading Update
3rd Jul 20237:00 amRNSChange of Registered Office
29th Jun 20234:46 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSCompletion of 100th development
27th Jun 20234:18 pmRNSHolding(s) in Company
27th Jun 20238:33 amRNSHolding(s) in Company
15th Jun 20237:31 amRNSScrip Calculation Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.